---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-025553"
form_type: "8-K/A"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2022-09-27T23:59:59+00:00"
generated_at: "2026-06-23T07:15:43.588932+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bioventus files CartiHeal audited financials: 2021 net loss $10.2M, zero revenue

## Summary
- CartiHeal had $0 revenue in 2021; net loss $10.2M; accumulated deficit $67.7M.
- R&D expenses $7.8M; cash and equivalents $4.9M at Dec 31, 2021.
- Acquisition closed July 12, 2022 for ~$315M upfront plus up to $135M in sales milestones.
- Unaudited pro forma combined financials reflect acquisition for six months ended July 2, 2022 and FY 2021.
- CartiHeal's Agili-C implant received FDA PMA in March 2022; pre-launch inventory provision of $642K reversed.

## SEC filing metadata
- accession: 0001628280-22-025553
- form_type: 8-K/A
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2022-09-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000162828022025553/0001628280-22-025553-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000162828022025553/bvs-20220712.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-025553
- JSON: https://secwatch.observer/filing/0001628280-22-025553.json
- Plain text: https://secwatch.observer/filing/0001628280-22-025553.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.